Abstract: Skin irritation, such as diaper rash, appearing when the skin is allowed to remain in contact with proteolytic enzymes found in feces is prevented by inactivating the fecal proteolytic enzymes by contact with organophilic clays. The organophilic clays are applied to the skin in areas likely to come into contact with feces or to garments such as diapers. A composition suitable for practicing the method of the invention comprises an amount of an organophilic clay effective to inactivate irritating fecal proteolytic enzymes dispersed in a pharmaceutically acceptable non-toxic dermatological vehicle. A fabric incorporating organophilic clay, preferably dispersed in a matrix of a superabsorbent polymer is useful for preparing diapers for infants that can help to prevent skin irritation by fecal enzymes.

Abstract: Implantable medical devices and drug delivery implants containing polyarylate random block copolymers are disclosed, along with methods for drug delivery and for preventing the formation of adhesions between injured tissues employing the polyarylate random block copolymers.

Abstract: Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.

Abstract: The present invention provides a composition for preventing or treating periodontal diseases comprising an extract of Achyranthis radix, Ulmus cortex or a mixture thereof which inhibits the productions of superoxide, prostaglandin, and interleukin (IL-1.beta.) which are inducers for periodontal diseases and inhibits the enzyme activity of collagenase which decomposes collagen protein which is a substrate for the periodontal tissues, and at the same time promotes collagen protein synthesis, thereby treating periodontal diseases efficiently.

Abstract: A composition for a skin patch including a synthetic polymer gel prepared by reacting a water-soluble polymer of an aliphatic carboxylic acid or a salt thereof with a sparingly soluble aluminum compound, an organic acid containing a hydroxyl group in its molecule as a reaction accelerator, and an ethylenediamine compound as a reaction inhibitor in the presence of water at a pH of 4.0 to 6.1. The composition can homogeneously gel at any crosslinking rate and does not cause any change in quality with the lapse of time.

Abstract: A novel delivery system for targeting drugs to the colon is herein described. The system is a tablet comprised of three parts: 1) an outer enteric coating, 2) an inner semi-permeable polymer membrane containing a plasticizer and 3) a central core comprising swelling excipients and an active ingredient. The novel dosage form described herein will release the drug consistently in the colon by a time-dependent explosion mechanism.This delivery system is particularly suitable for delivering viral protease inhibitors to the colon.

Abstract: The invention provides a process for the removal and recovery of zinc from an aqueous process stream. In particular, the process of the invention is useful in the removal and recovery of zinc compounds such as zinc chloride from an aqueous effluent stream produced in various manufacturing processes such as the manufacture of sorbic acid.

Abstract: The present invention relates to cosmetic or pharmaceutical compositions comprising a magnetic metal species bound to an ion exchange resin as well as a method for preparing stable compositions of this type.

Abstract: A method of providing a patient needing clonidine with an extended dosage of clonidine over a prolonged period of time. Such method involves administering to the patient an oral dosage unit comprising a homogenous mixture of a therapeutically effective amount of clonidine, about 30 to about 70 percent by weight of one or more cellulose ethers such as hydroxypropyl methylcellulose, and about 30 to about 70 percent by weight of an inert substance such as cornstarch. The oral dosage unit may be contained in a gelatin capsule or in the form of a tablet.

Abstract: The invention is directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier, the hydrogel component of the carrier ranging from about 0.3 to 3.0% of the composition and having a molecular weight of about at least 10,000 Daltons. The composition contains about 25% to about 40% bone powder and can be additionally provided with BMP's and a sodium phosphate buffer.

Abstract: The present invention general relates to thermally responsive polymer gel compositions that have enhanced temperature-dependent shrinking rates, increased strength, and improved pliability over previously known polymer compositions. In particular, the compositions are thermally responsive polymer gel compositions comprising a hydrophobic polymer matrix and an interpenetrating hydrophilic polymer network disposed therein, such that the resulting polymer gel composition has enhanced thermal responsiveness relative to the hydrophobic polymer matrix alone. This combination results in polymer gels having these improved properties. In a particular aspect, the hydrophobic polymer matrix is poly(n-isopropylacrylamide) ("PNIPAAM") and the interpenetrating polymer network is supplied by incorporation of an amount of protein, typically gelatin, within the PNIPAAM. The compositions of the invention find particular use in surgical applications for the repair of damaged tissues, e.g.

Abstract: A synergistic anti-bacterial composition, including: (a) an extract of botanical materials, the botanical materials including material from Plantago species, Hypericum species, Echinacea species and Propolis; and (b) oil of cinnamon.

Abstract: A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.

Abstract: An aqueous cosmetic composition containing uric acid in a stably solubilized state together with an acrylic polymer is disclosed. The composition is adjusted to pH equal to or higher than pK.sub.1 of uric acid, in particular, pH 7 or higher by an alkali to solubilize uric acid. A method for stably solubilizing uric acid in an aqueous cosmetic composition is also disclosed.

Abstract: The present invention relates to leave on, skin care compositions, comprising: (a) from about 0.1% to about 30% of a sunscreen active, (b) from about 0.5% to about 20% of a hydrophobic, structuring agent, (c) from about 0.2% to about 10% of a hydrophilic surfactant, (d) from about 0.1% to about 5% of a thickening agent, (e) from about 0.1% to about 25% of a skin lightening agent and (f) water. These compositions are useful for providing (i) protection to human skin from the harmful effects of ultraviolet radiation and (ii) a skin lightening benefit.

Abstract: A formulation having a rose hip concentrate is used to treat and/or alleviate the symptoms associated with inflammation including arthritis or to prevent development of arthritis. The rose hip concentrate has a high vitamin content relative to conventionally dried material, and is shown, in vitro, to inhibit the chemotaxis and oxidative burst response of human peripheral blood inflammatory cells, as well as the chemotaxis of monocytes. The formulation, in vivo, was found to inhibit chemotaxis of human peripheral blood inflammatory cells and to reduce the level of C-reactive protein, to alleviate pain and reduce inflammation in patients with arthritis.

Abstract: The present invention relates to a pharmaceutical composition comprising anion exchange resin, silicon dioxide, crystalline cellulose, and pharmaceutically acceptable carriers and more particularly to tablets containing anion exchange resin prepared by mixing anion exchange resin, silicon dioxide and crystalline cellulose without adding water and tabletting the mixture. More preferably, the present invention relates to said pharmaceutical composition or tablets wherein the anion exchange resin is non-crosslinked anion exchange resin represented by the formula (I): ##STR1## wherein R.sub.1 is an aralkyl group having from 7 to 10 carbon atoms or An alkyl group having from 1-20 carbon atoms; R.sub.2 and R.sub.3 are each independently the same or different and represent a lower alkyl group having from 1-4 carbon atoms; R.sub.

Abstract: The present invention relates to the use of a bioadhesive aqueous composition to control the pH of the vagina to alleviate microorganism growth and feminine odor such as presented by bacterial vaginosis. The composition contemplated herein comprises water and an acidic polymer, specifically one wherein 80% of the monomers contain at least one carboxyl group [--COOH] and wherein the polymer is cross-linked so as to be water-swellable, but water-insoluble. The composition of the present invention is additionally a bioadhesive providing for a long-lasting benefit and control of vaginal pH.

Abstract: A pharmaceutical dental formulation of therapeutically effective amounts of metronidazole benzoate and chlorhexidine gluconate is described. The formulation also includes a gelled hydrophilic and water-dipersible polymer having free carboxylic groups, an aqueous base, a penetration enhancer and a chelating agent. The formulation is for topical application in the form of an aqueous gel in the treatment of periodontal diseases including gingivitis, stomatitis, Apthous ulcers and post-extraction infection.

Abstract: The present invention describes stable water-in-oil emulsions comprising the following components: water, oil, a labile compound of interest, a stabilizing agent and an emulsifier. The labile compound present in the water phase is stabilized by addition of a stabilizing agent which preferably is a polyol. Specific emulsifiers are described which give rise to stable emulsions in the presence of high amounts of a polyol.